Allogene Therapeutics Inc.(ALLO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALLO Allogene Therapeutics Inc.

休市中 08-14 16:00:00 EDT

2.05

+0.07

+3.54%

盘后2.06

+0.01+0.49%

19:34 EDT

最高2.08	最低1.92	成交量460.51万
今开1.96	昨收1.98	日振幅8.08%
总市值7.07亿	流通市值5.45亿	总股本3.45亿
成交额930.37万	换手率1.73%	流通股本2.66亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALLO","market":"US","secType":"STK","nameCN":"Allogene Therapeutics Inc.","latestPrice":2.05,"timestamp":1786737600000,"preClose":1.98,"halted":0,"volume":4605146,"hourTrading":{"tag":"盘后","latestPrice":2.06,"preClose":2.05,"latestTime":"19:34 EDT","volume":12604,"amount":25921.7986,"timestamp":1786750445981,"change":0.01,"changeRate":0.004878,"amplitude":0.027561},"delay":0,"changeRate":0.035353535353535276,"floatShares":266000000,"shares":345000000,"eps":-0.651017,"marketStatus":"休市中","change":0.07,"latestTime":"08-14 16:00:00 EDT","open":1.96,"high":2.08,"low":1.92,"amount":9303684.8213946,"amplitude":0.080808,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.651017,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1539230400000,"exchange":"NASDAQ","adjPreClose":1.98,"preHourTrading":{"tag":"盘前","latestPrice":1.9633,"preClose":1.98,"latestTime":"09:19 EDT","volume":7881,"amount":15493.131804,"timestamp":1786713552404,"change":-0.0167,"changeRate":-0.008434,"amplitude":0.015101},"postHourTrading":{"tag":"盘后","latestPrice":2.06,"preClose":2.05,"latestTime":"19:34 EDT","volume":12604,"amount":25921.7986,"timestamp":1786750445981,"change":0.01,"changeRate":0.004878,"amplitude":0.027561},"volumeRatio":0.923223,"impliedVol":0.6805,"impliedVolPercentile":0.1315},"requestUrl":"/m/hq/s/ALLO","defaultTab":"news","newsList":[{"id":"2658601830","title":"UPBIT 上线 CYS、ICNT、XAN、EDEN、AIOZ、ALLO 并支持 BTC、USDT 交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2658601830","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658601830?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:06","pubTimestamp":1786327600,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，UPBIT 将于 8 月 10 日 14:00 上线 CYS、ICNT、XAN、EDEN、AIOZ、ALLO 交易，并支持 BTC、USDT 交易对。用户需在公告发布后 2 小时内完成充值。 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2281694","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTCI","IBIT","BPI","BK4139","DEFI","BTC.USD.CC","MAXI","BTC","BTRN","CBOO","BFJL","SBIT","BTFX","CBTJ","BRRR","ARKB","DFII","CBTY","XBTY","BFAP","BITU","EDEN","CBTO","CBOY","BETH","BTCW","BK4505","BITO","CYS","GBTC","BTCO","BTF","BETE","CBXJ","ALLO","CBXY","EZBC","BAGY","BITI","BTCC","BITY","BITB","BTCZ","CBXA","CBOJ","CBOA","CBXO","MNRS","QBF","YBTC","FBTC","BCCC","HODL","BITX","CBTA","BTCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656756589","title":"RootData：ALLO 将于一周后解锁价值约 450 万美元的代币","url":"https://stock-news.laohu8.com/highlight/detail?id=2656756589","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656756589?lang=zh_cn&edition=full","pubTime":"2026-08-04 11:00","pubTimestamp":1785812402,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据Web3资产数据平台 RootData 代币解锁数据，Allora（ALLO）将于北京时间 08 月 11 日 0 时解锁约 1725 万枚代币，价值约 450 万美元。 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2280274","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","ALLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140534356","title":"Allogene Therapeutics：Cema-Cel未报告治疗相关严重不良事件或高级别感染","url":"https://stock-news.laohu8.com/highlight/detail?id=1140534356","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140534356?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:36","pubTimestamp":1785328568,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics（ALLO）发布消息：其候选药物Cema-Cel未出现任何治疗相关的严重不良事件或高级别感染报告。这一进展备受关注，因为安全性一直是细胞疗法领域的核心议题。目前，公司正积极推进相关临床研究，力求为患者提供更安全的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLO","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103958552","title":"Allogene Therapeutics候选药物Cema-Cel获FDA再生医学先进疗法认定，用于大B细胞淋巴瘤一线巩固治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1103958552","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103958552?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:31","pubTimestamp":1785328271,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics公司近日宣布，其候选药物cemacabtagene ansegedleucel（简称Cema-Cel）已获得美国食品药品监督管理局（FDA）授予的再生医学先进疗法（RMAT）认定。该药物将作为大B细胞淋巴瘤患者的一线巩固治疗药物。这一认定标志着该疗法在开发过程中迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","ALLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108497806","title":"Allogene Therapeutics宣布《临床肿瘤学杂志》发表Allo-316一期结果，凸显异体CAR-T治疗转移性实体瘤首次实现持久缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1108497806","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108497806?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:31","pubTimestamp":1784118682,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics Inc.  宣布，其研究性药物Allo-316的一期临床试验结果已在权威医学期刊《临床肿瘤学杂志》上发表。该研究数据首次表明，利用同种异体CAR-T细胞疗法治疗转移性实体瘤可获得持久缓解，标志着该领域的一个重要里程碑。此项研究聚焦于Allo-316在晚期实体瘤患者中的安全性与初步疗效。这些发现不仅验证了异体CAR-T技术的潜力，也为后续的临床开发奠定了坚实的基础。公司表示，这一成果进一步推动了其利用现成的、可规模化生产的CAR-T疗法治疗实体瘤的战略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLO","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648695174","title":"RootData：ALLO 将于一周后解锁价值约 598 万美元的代币","url":"https://stock-news.laohu8.com/highlight/detail?id=2648695174","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648695174?lang=zh_cn&edition=full","pubTime":"2026-07-04 11:00","pubTimestamp":1783134001,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据Web3资产数据平台 RootData 代币解锁数据，Allora（ALLO）将于北京时间 07 月 11 日 0 时解锁约 1725 万枚代币，价值约 598 万美元。 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2274892","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLO","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640139343","title":"RootData：ALLO 将于一周后解锁价值约 315 万美元的代币","url":"https://stock-news.laohu8.com/highlight/detail?id=2640139343","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640139343?lang=zh_cn&edition=full","pubTime":"2026-06-04 11:00","pubTimestamp":1780542001,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据Web3资产数据平台 RootData 代币解锁数据，Allora（ALLO）将于北京时间 06 月 11 日 0 时解锁约 1725 万枚代币，价值约 315 万美元。 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2269120","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLO","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174808881","title":"Allogene Therapeutics Inc. 终止与Overland Therapeutics的独家许可协议，自2026年5月12日起生效 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1174808881","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174808881?lang=zh_cn&edition=full","pubTime":"2026-05-14 04:48","pubTimestamp":1778705300,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件披露，生物技术公司Allogene Therapeutics Inc. 已正式终止其与Overland Therapeutics达成的独家许可协议。此项终止决定将于2026年5月12日正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","ALLO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103706403","title":"Allogene Therapeutics Inc. 将持有Overland约3%股权 此前无偿放弃部分股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1103706403","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103706403?lang=zh_cn&edition=full","pubTime":"2026-05-14 04:44","pubTimestamp":1778705052,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，Allogene Therapeutics Inc. 在无偿放弃其持有的部分Overland公司股权后，将保留约3%的股份。此举调整了该公司在Overland的持股比例。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","ALLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100548946","title":"Allogene Therapeutics Inc.：终止协议未涉及任何解约付款——根据SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1100548946","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100548946?lang=zh_cn&edition=full","pubTime":"2026-05-14 04:43","pubTimestamp":1778704999,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件显示，生物技术公司Allogene Therapeutics Inc.在其终止协议的执行过程中，并未支付任何形式的解约款项。这一披露明确了相关财务安排，避免了潜在的费用支出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","ALLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632987800","title":"RootData：ALLO 将于一周后解锁价值约 214 万美元的代币","url":"https://stock-news.laohu8.com/highlight/detail?id=2632987800","media":"链捕手","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632987800?lang=zh_cn&edition=full","pubTime":"2026-05-04 11:00","pubTimestamp":1777863601,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据Web3资产数据平台 RootData 代币解锁数据，Allora（ALLO）将于北京时间 05 月 11 日 0 时解锁约 1725 万枚代币，价值约 214 万美元。 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2262358","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","ALLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137659418","title":"Allogene Therapeutics宣布拟公开发行1.75亿美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1137659418","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137659418?lang=zh_cn&edition=full","pubTime":"2026-04-14 05:04","pubTimestamp":1776114277,"startTime":"0","endTime":"0","summary":"4月13日——Allogene Therapeutics Inc宣布计划启动一项规模达1.75亿美元的普通股公开发行。该公司表示，此次发行所得净资金将用于企业一般运营需求，包括临床试验推进及研发项目投入。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLO","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130639189","title":"Allogene Therapeutics Inc. 预计将净收益用于一般企业用途 涵盖临床试验与研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1130639189","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130639189?lang=zh_cn&edition=full","pubTime":"2026-04-14 04:07","pubTimestamp":1776110823,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics Inc. 计划将此次融资的净收益主要用于公司一般运营需求。这些资金将支持多项核心业务活动，其中重点包括推进临床试验项目及持续投入研发工作。此举旨在加速公司创新疗法的开发进程，强化其在细胞治疗领域的技术优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALLO","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190138917","title":"Allogene Therapeutics公布ALPHA3关键试验中期无效性分析结果：一线巩固治疗LBCL中Cemacabtagene Ansegedleucel（Cema-Cel）微小残留病灶清除率达58.3%，观察组仅为16.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190138917","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190138917?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:33","pubTimestamp":1776080038,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics Inc.（纳斯达克代码：ALLO）今日披露了其关键性ALPHA3试验的中期无效性分析数据。研究显示，在一线巩固治疗大B细胞淋巴瘤（LBCL）患者中，实验性疗法Cemacabtagene Ansegedleucel（简称Cema-Cel）展现出显著优势。\n具体数据显示，接受Cema-Cel治疗的患者组中，微小残留病灶（MRD）清除率达到58.3%。这一结果远高于观察组的16.7%，凸显了该细胞疗法的潜在疗效。试验结果为进一步评估Cema-Cel在淋巴瘤治疗领域的应用价值提供了重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLO","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121519199","title":"Allogene Therapeutics将公布2025年第四季度及全年财报并举行业务进展说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1121519199","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121519199?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:31","pubTimestamp":1772458279,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics Inc.（纳斯达克：ALLO）近日宣布，公司计划于近期披露2025财年第四季度及全年度的财务业绩报告。此次公告将同步召开业务进展说明会，向投资者全面解读公司最新研发动态与战略规划。\n作为专注于同种异体CAR-T疗法开发的生物技术企业，此次财报发布将揭示其核心产品管线的临床推进情况与资金运营状况。管理层将通过电话会议深入分析财务数据，并回答机构投资者关于临床试验里程碑、监管审批路径等关键议题的提问。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","ALLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518320385","title":"Allogene Therapeutics, Inc.盘中异动 股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518320385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518320385?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:06","pubTimestamp":1741626373,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时06分，Allogene Therapeutics, Inc.股票出现异动，股价快速下挫5.05%。Allogene Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。Allogene Therapeutics, Inc.公司简介：Allogene Therapeutics Inc是一家专门从事免疫肿瘤学的临床阶段生物技术公司，专注于开发用于癌症和自身免疫性疾病的基因工程同种异体T细胞产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503110106139640612d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503110106139640612d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","ALLO","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517192780","title":"Allogene Therapeutics, Inc.盘中异动 急速拉升5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517192780","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517192780?lang=zh_cn&edition=full","pubTime":"2025-03-07 03:48","pubTimestamp":1741290532,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日03时48分，Allogene Therapeutics, Inc.股票出现异动，股价大幅上涨5.18%。Allogene Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.56%。Allogene Therapeutics, Inc.公司简介：Allogene Therapeutics Inc是一家专门从事免疫肿瘤学的临床阶段生物技术公司，专注于开发用于癌症和自身免疫性疾病的基因工程同种异体T细胞产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307034853a262db6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307034853a262db6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","ALLO","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516709766","title":"Allogene Therapeutics, Inc.盘中异动 早盘大幅下跌5.56%报1.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516709766","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516709766?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:00","pubTimestamp":1741100428,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时00分，Allogene Therapeutics, Inc.股票出现波动，股价快速跳水5.56%。Allogene Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。Allogene Therapeutics, Inc.公司简介：Allogene Therapeutics Inc是一家专门从事免疫肿瘤学的临床阶段生物技术公司，专注于开发用于癌症和自身免疫性疾病的基因工程同种异体T细胞产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030423002996394d5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030423002996394d5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","ALLO","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514933209","title":"Allogene Therapeutics, Inc.盘中异动 下午盘股价大跌5.15%报1.94美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514933209","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514933209?lang=zh_cn&edition=full","pubTime":"2025-02-28 04:29","pubTimestamp":1740688154,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日04时29分，Allogene Therapeutics, Inc.股票出现波动，股价快速跳水5.15%。Allogene Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.38%。Allogene Therapeutics, Inc.公司简介：Allogene Therapeutics Inc是一家专门从事免疫肿瘤学的临床阶段生物技术公司，专注于开发用于癌症和自身免疫性疾病的基因工程同种异体T细胞产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280429149632f210&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280429149632f210&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","ALLO","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514851245","title":"Allogene Therapeutics, Inc.盘中异动 大幅拉升5.04%报2.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514851245","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514851245?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:05","pubTimestamp":1740582333,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时05分，Allogene Therapeutics, Inc.股票出现波动，股价快速拉升5.04%。Allogene Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.15%。Allogene Therapeutics, Inc.公司简介：Allogene Therapeutics Inc是一家专门从事免疫肿瘤学的临床阶段生物技术公司，专注于开发用于癌症和自身免疫性疾病的基因工程同种异体T细胞产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262305339893b1a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262305339893b1a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","ALLO","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.allogene.com","stockEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0789},{"period":"3month","weight":0.025},{"period":"6month","weight":0.1389},{"period":"1year","weight":0.9159},{"period":"ytd","weight":0.4964}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Allogene Therapeutics, Inc.于2017年11月30日在特拉华州成立，总部位于加利福尼亚州南旧金山。该公司是一家临床阶段免疫肿瘤学公司，开创了用于治疗癌症的基因工程异体T细胞疗法的开发和商业化。公司正在开发一种现成的T细胞候选产品系列，旨在靶向和杀死癌细胞。Allogene Therapeutics, Inc.工程改造的T细胞是同种异体的，这意味着来自健康供体，用于任何患者，而不是来自患者的个体患者，如自体T细胞的情况。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.07707},{"month":2,"riseRate":0.75,"avgChangeRate":0.112372},{"month":3,"riseRate":0.125,"avgChangeRate":-0.130043},{"month":4,"riseRate":0.5,"avgChangeRate":0.006921},{"month":5,"riseRate":0.25,"avgChangeRate":-0.01113},{"month":6,"riseRate":0.375,"avgChangeRate":0.021016},{"month":7,"riseRate":0.5,"avgChangeRate":0.030413},{"month":8,"riseRate":0.375,"avgChangeRate":-0.039834},{"month":9,"riseRate":0.714286,"avgChangeRate":-0.014156},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.088172},{"month":11,"riseRate":0.375,"avgChangeRate":0.02598},{"month":12,"riseRate":0.125,"avgChangeRate":-0.099527}],"exchange":"NASDAQ","name":"Allogene Therapeutics Inc.","nameEN":"Allogene Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Allogene Therapeutics Inc.(ALLO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Allogene Therapeutics Inc.(ALLO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Allogene Therapeutics Inc.,ALLO,Allogene Therapeutics Inc.股票,Allogene Therapeutics Inc.股票老虎,Allogene Therapeutics Inc.股票老虎国际,Allogene Therapeutics Inc.行情,Allogene Therapeutics Inc.股票行情,Allogene Therapeutics Inc.股价,Allogene Therapeutics Inc.股市,Allogene Therapeutics Inc.股票价格,Allogene Therapeutics Inc.股票交易,Allogene Therapeutics Inc.股票购买,Allogene Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Allogene Therapeutics Inc.(ALLO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Allogene Therapeutics Inc.(ALLO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}